Fig. 2: Atezolizumab impairs the function of mitochondria to cause the imbalance between oxidants and antioxidants.
From: Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma
A Transmission electron microscopy of HOS and 143B after the treatment of atezolizumab (10 µg/ml) (red arrows point to mitochondria); B Mitochondrial membrane potential of HOS and 143B was detected by JC-1 staining after the treatment of atezolizumab (normal OS cells which have high ΔΨm show strong red fluorescence and weak green fluorescence); C Quantification of JC-1 staining in HOS and 143B; D, E Release of ROS in HOS and 143B was detected by flow cytometry after the treatment of atezolizumab; F Amount of SOD in HOS and 143B was detected by the total SOD assay kit. All data are from at least three independent experiments and are presented as the means ± SD. *P < 0.05; **P < 0.01; ***P < 0.001.
